Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials

Chen, Junyu; Zhuang, Xiaodong; Long, Ming; Su, Chen; Wang, Lichun

doi:10.1016/j.jstrokecerebrovasdis.2015.07.026

Cited by 5 publications

(4 citation statements)

References 33 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a large comprehensive meta-analysis, combining all the edoxaban studies performed in NVAF patients, confirmed that edoxaban had the same efficacy and a better safety profile than warfarin in treating thromboembolic risk. 35 In particular, this meta-analysis confirmed that the better safety profile was consistent independently of the type of bleeding event (major/minor/clinically relevant nonmajor bleeding). In the same paper, a direct comparison between the two edoxaban regimens showed that both low- and high-dose edoxaban were effective in reducing both thromboembolic events and all-cause mortality.…”

Section: Edoxaban In Nonvalvular Atrial Fibrillationsupporting

confidence: 64%

See 1 more Smart Citation

Edoxaban in venous thromboembolism and stroke prevention: an appraisal

Proietti¹,

Lip²

2016

VHRM

View full text Add to dashboard Cite

Oral anticoagulation is the therapeutic cornerstone in preventing thromboembolic risk in both atrial fibrillation (AF) and venous thromboembolism (VTE). After decades of the sole therapeutic oral anticoagulation option being warfarin, the introduction of non-vitamin K antagonist oral anticoagulants has heralded a new era. Edoxaban is the latest addition to these available for clinical use. Edoxaban was as effective and safer than warfarin in preventing thromboembolic risk in AF patients. Similarly, edoxaban effectiveness and safety was evident when treating VTE patients to prevent recurrent VTE or VTE-related death. Therefore, edoxaban represents a valuable alternative in treating thromboembolic risk for AF and VTE patients.

show abstract

Section: Edoxaban In Nonvalvular Atrial Fibrillationsupporting

confidence: 64%

“…In the same paper, a direct comparison between the two edoxaban regimens showed that both low- and high-dose edoxaban were effective in reducing both thromboembolic events and all-cause mortality. 35 Last, edoxaban 30 mg was associated with a lower incidence of all bleeding events. 35 …”

Section: Edoxaban In Nonvalvular Atrial Fibrillationmentioning

confidence: 97%

Edoxaban in venous thromboembolism and stroke prevention: an appraisal

Proietti¹,

Lip²

2016

VHRM

View full text Add to dashboard Cite

show abstract

“…For instance, studies in Asia and Europe found significantly higher satisfaction scores for DOACs according to PACT-Q2 than for warfarin. 14 , 23 , 24 , 29 These studies included patients aged 18 and older, and with fewer comorbidities, particularly mental health concerns, than patients treated in the VA. 30 By assessing the perspectives of VA patients with dementia or serious mental illness residing in non-institutional settings, we made a meaningful contribution to the literature as these vulnerable patients are often overlooked in research. Variation in results from our study population and prior work highlights the need to assess perspectives in diverse groups of patient with AFib to accurately inform shared decision-making.…”

Section: Discussionmentioning

confidence: 99%

“…We add to other studies providing evidence that the PACT-Q2 reliably measures patient’s perceptions of satisfaction and convenience with respect to their anticoagulation use. 14 , 23 – 25 , 29 As more evidence develops regarding the value of various novel anticoagulant medications, the PACT-Q2 may continue to provide utility in assessing patient perceptions. Our study also has the advantage of including qualitative interviews to further understand the factors underlying convenience and satisfaction ratings in the survey.…”

Section: Discussionmentioning

confidence: 99%

<p>Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants</p>

Mull¹,

Shin²,

Engle³

et al. 2020

PPA

View full text Add to dashboard Cite

Background: Atrial fibrillation (AFib) is associated with high morbidity and mortality. Traditionally, AFib was treated with warfarin, yet recent evidence suggests patients may favor direct oral anticoagulants (DOACs). Variation in preferences is common and we explored patients' perceptions of satisfaction and convenience of DOACs versus warfarin within the Veterans Health Administration (VA). Patients and Methods: We administered a cross-sectional survey, the Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2), to Veterans residing in New England, age ≥65, diagnosed with AFib, and actively taking anticoagulant medication in fiscal year 2018. Survey recipients were randomly selected among patients on warfarin (n=200) or DOACs (n=200). A selection of survey respondents agreed to a follow-up semistructured interview (n=16) to further investigate perceptions of satisfaction and convenience. Results: Of 400 patients, 187 completed the PACT-Q2 survey (49% on DOACs; 51% on warfarin). DOACs received significantly higher convenience ratings than warfarin (87.6, SD 13.5 vs 81.1, SD 18.8; p=0.007); there was no difference in satisfaction (64.2, SD 20.5 SD, warfarin vs, 67.3, SD 19.4, DOACs). Interview results showed that participants perceived their treatment to be convenient. However, participants expressed challenges related to the convenience of taking warfarin or DOACs, such as warfarin users having to follow dietary recommendations or DOAC users desiring some additional monitoring to answer questions or concerns. Overall, warfarin and DOAC users reported satisfaction with ongoing monitoring methods, although a few DOAC users expressed uncertainties with the frequency of monitoring. For most participants, concerns about side effects did not differ by anticoagulant type nor affect satisfaction. Conclusion: Our survey and interview results showed variable patient satisfaction and perceptions of convenience with both DOACs and warfarin. Although DOACs are increasingly prescribed for AFib, some Veterans felt that regular follow-up on warfarin was advantageous. Our findings demonstrate the importance of patient-centered decisionmaking in AFib treatment in the VA patient population.

show abstract

Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis

Chen

et al. 2023

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials

Cited by 5 publications

References 33 publications

Edoxaban in venous thromboembolism and stroke prevention: an appraisal

Edoxaban in venous thromboembolism and stroke prevention: an appraisal

<p>Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants</p>

Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis

Contact Info

Product

Resources

About